Amneal Pharmaceuticals (AMRX) AI Stock Analysis

• Market Cap: $4.00B
• Dividend Yield: N/A
• Average Volume (3M): 3.35M
• Price to Earnings (P/E): 54.8
• Beta (1Y): 0.88
• Revenue Growth: 9.50%
• EPS Growth: N/A
• Country: US
• Employees: 8,300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.21
• Shares Outstanding: 314,629,100
• 10 Day Avg. Volume: 2,145,359
• 30 Day Avg. Volume: 3,354,234
• PEG Ratio: -0.34
• Price to Book (P/B): -55.77
• Price to Sales (P/S): 1.31
• P/FCF Ratio: 14.63
• Enterprise Value/Market Cap: 1.56
• Enterprise Value/Revenue: 2.07
• Enterprise Value/Gross Profit: 5.60
• Enterprise Value/Ebitda: 10.33
• 1Y Price Target: $17.33
• Price Target Upside: 36.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.96
• Revenue Forecast (FY): $3.12B

• Rating: 54 Neutral
• Price Target: $14.00 ▲(10.15% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is held back mainly by weak valuation (very high P/E) and a still-mixed financial profile marked by historically stressed balance-sheet periods and volatile profitability, despite improving cash generation. Earnings-call guidance is constructive with expected margin/earnings growth and continued deleveraging, but technical signals show cautious near-term momentum.

Positive Factors

Cash Generation

Amneal has produced positive operating and free cash flow in most years with a strong rebound since 2023. Reliable FCF supports capital spending, debt reduction and strategic investments (biosimilars, GLP‑1 plants), providing a durable funding source for growth and deleveraging.

High‑value Pipeline & Complex Launches

A large pipeline weighted to complex generics and biosimilars signals structural shift toward higher‑barrier products. Successful complex launches and biosimilars should deliver stickier revenues and better margins over time, improving portfolio durability versus plain‑vanilla generics.

Improving Capital Structure and Lower Interest Costs

Recent term‑loan repricing and meaningful debt reduction cut interest expense and extended maturities, lowering financing risk. Reduced annual cash interest and net leverage improvement increase financial flexibility to fund launches and R&D without immediate refinancing pressure.

Negative Factors

Historical Balance‑Sheet Stress

Amneal's track record includes periods of very high leverage and even negative equity, which undermines resilience. Though balance sheet metrics improved in 2025, the history of volatility means any operational setback could quickly erode flexibility and force costly financing or asset actions.

Execution & Timing Risk

The company’s growth story rests on numerous forward‑looking milestones (biosimilars, GLP‑1 manufacturing with Pfizer, many complex ANDA launches). Slips in approvals, manufacturing ramps or commercialization timing would delay revenue and margin benefits and magnify downside risk.

AvKARE Revenue Reset / Concentration Risk

Management forecasts a deliberate AvKARE revenue reset in 2026, reducing a high‑revenue government/distribution channel. That near‑term top‑line decline and concentration in AvKARE make cash flow and margin progress sensitive to replacement from specialty and other segments.

Amneal Pharmaceuticals Business Overview & Revenue Model

Company Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

How the Company Makes Money

Amneal Pharmaceuticals generates revenue primarily through the sale of generic and specialty pharmaceutical products. Its key revenue streams include the commercialization of generic drugs, which are sold at competitive prices to pharmacies, wholesalers, and healthcare providers. The company also earns revenue from specialty products that often entail higher margins compared to generic offerings, particularly in therapeutic areas that require more complex formulations. Additionally, Amneal benefits from strategic partnerships and collaborations with other pharmaceutical companies, which can enhance its product offerings and expand market reach. The company’s commitment to research and development allows it to continuously innovate and bring new products to market, contributing to long-term revenue growth.

Amneal Pharmaceuticals Financial Statement Overview

Summary

Steady revenue growth and resilient gross margins, with cash flow a clear strength (positive operating and free cash flow in most years and a strong rebound since 2023). However, profitability has been volatile (losses in 2022–2024 and near-breakeven operating profit in 2025 despite positive net income), and the balance sheet has a history of stress (including negative equity in 2024) even though 2025 shows meaningful deleveraging and a return to positive equity.

Income Statement

Revenue has grown consistently from 2021–2025 (with a strong 2025 annual growth rate of ~2.9% off a larger base), and gross margin has been steady in the mid-to-high 30% range, indicating resilient product economics. However, profitability has been volatile: net results swung from profits (2020, 2021, 2025) to losses (2022–2024), and 2025 operating profit was essentially breakeven/negative while net income was positive—suggesting earnings quality and cost structure still need stabilization.

Balance Sheet

Leverage risk has been a key overhang historically, with very high debt relative to equity in 2020–2023 and negative equity in 2024, which materially weakens financial flexibility. The 2025 balance sheet shows a major improvement (debt down sharply and a return to positive equity, with debt-to-equity at ~0.14), but the prior years’ stressed capital structure and large swings in equity/returns point to elevated balance-sheet volatility and execution risk.

Cash Flow

Cash generation is a relative strength: operating cash flow and free cash flow are positive in most years, with a strong rebound since 2023 and double-digit free-cash-flow growth in 2025. Free cash flow has generally tracked a large portion of net income (and remained solid even when earnings were negative in some years), supporting liquidity. The main weakness is inconsistency—2022 saw weak operating cash flow and negative free cash flow—so cash conversion has not been uniformly stable across the cycle.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.02B	2.79B	2.39B	2.21B	2.09B
Gross Profit	1.14B	1.02B	863.87M	791.46M	768.97M
EBITDA	603.87M	439.77M	500.78M	440.21M	401.10M
Net Income	72.06M	-116.89M	-83.99M	-129.99M	10.62M
Balance Sheet
Total Assets	3.68B	3.50B	3.47B	3.80B	3.94B
Cash, Cash Equivalents and Short-Term Investments	310.87M	112.42M	93.74M	27.80M	247.79M
Total Debt	2.74B	2.59B	2.75B	2.85B	2.88B
Total Liabilities	3.67B	3.55B	3.41B	3.59B	3.57B
Stockholders Equity	-70.79M	-109.27M	19.78M	298.42M	360.34M
Cash Flow
Free Cash Flow	269.93M	220.11M	276.39M	-25.50M	194.09M
Operating Cash Flow	339.99M	295.10M	345.58M	65.10M	241.82M
Investing Cash Flow	-112.26M	-63.00M	-69.19M	-174.31M	-194.18M
Financing Cash Flow	-31.53M	-211.79M	-212.57M	-106.62M	-138.12M

Amneal Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.71
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRX, the sentiment is Neutral. The current price of 12.71 is below the 20-day moving average (MA) of 14.07, below the 50-day MA of 13.76, and above the 200-day MA of 10.74, indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 29.24 is Positive, neither overbought nor oversold. The STOCH value of 18.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMRX.

Amneal Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANIP	67 Neutral	$1.71B	14.40	15.55%	―	48.87%	―
SUPN	60 Neutral	$3.06B	-72.78	-0.01%	―	4.54%	-130.59%
AMPH	59 Neutral	$851.60M	12.76	12.76%	―	-0.03%	-27.66%
AMRX	54 Neutral	$4.00B	54.80	-67.91%	―	9.50%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	50 Neutral	$1.35B	-1.35	-35.16%	8.48%	-2.55%	66.00%
ALVO	42 Neutral	$1.11B	-117.81	-26.11%	―	55.38%	―

Amneal Pharmaceuticals Corporate Events

Amneal Posts Strong Q4 Results and Raises 2026 Outlook

On February 27, 2026, Amneal reported that fourth-quarter 2025 net revenue rose 11% year over year to $814 million, with GAAP net income swinging to a $35 million profit from a $31 million loss and adjusted EBITDA climbing 13% to $175 million. Specialty sales jumped 38% on strong uptake of CREXONT and UNITHROID, while Affordable Medicines slipped 1% and AvKARE grew 24%, highlighting the firm’s shift toward higher-margin branded and government-channel businesses.

For full-year 2025, net revenue increased 8% to $3.02 billion and net income improved to $72 million from a $117 million loss, as adjusted EBITDA rose 10% to $688 million and adjusted diluted EPS advanced to $0.83 from $0.58. Management’s 2026 guidance calls for modest top-line growth to $3.05–$3.15 billion and further margin expansion, signaling confidence in continued gains from new product launches, particularly in Affordable Medicines and AvKARE, and reinforcing Amneal’s trajectory of six consecutive years of execution and growth.

The most recent analyst rating on (AMRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Amneal Pharmaceuticals Refinances Term Loans, Lowers Interest Costs

On February 2, 2026, Amneal Pharmaceuticals’ subsidiary, Amneal Pharmaceuticals LLC, and certain of its subsidiaries entered into a second amendment to their November 14, 2023 term loan credit agreement, refinancing and partially converting existing term loans into approximately $2.09 billion of new Amendment No. 2 Term Loans while keeping the August 1, 2032 maturity date unchanged. The repricing lowered the interest rate margins on the amended term loans by 50 basis points—to 2.00% over the base rate and 3.00% over the secured overnight financing rate—and introduced the ability to reprice the debt after August 2, 2026 without a prepayment premium, changes the company estimates will reduce its annual cash interest expense by about $11 million, strengthening its capital structure and lowering ongoing financing costs for stakeholders.

The most recent analyst rating on (AMRX) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Amneal Finalizes Nationwide Opioid Settlement Implementation Plan

On January 23, 2026, Amneal Pharmaceuticals said it would implement a nationwide opioids settlement after securing sufficient participation from all eligible state and territorial attorneys general and all subdivisions that had sued the company, with the agreement becoming effective on January 29, 2026. Under the settlement, Amneal will pay participating states and local governments $88.5 million and provide up to $177.4 million worth of naloxone nasal spray to treat opioid overdoses, with an option for settling parties to receive 25% of the naloxone’s value in cash during the final four years of the ten-year payment term, potentially raising the total cash outlay to as much as $132.9 million and helping the company resolve a substantial majority of its opioid-related liabilities.

The most recent analyst rating on (AMRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report

On January 13, 2026, Amneal Pharmaceuticals, Inc. filed a report under the Securities Exchange Act of 1934, formally executed on behalf of the company by Executive Vice President and Chief Financial Officer Anastasios Konidaris, who also serves as the principal financial and accounting officer. The filing, which incorporates financial disclosure from another section by reference, represents a routine but important procedural step in the company’s ongoing financial reporting and regulatory compliance obligations, underscoring the CFO’s central role in certifying Amneal’s public disclosures for investors and regulators.

The most recent analyst rating on (AMRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.